Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Feature|Videos|August 13, 2025
Advances across urology: Insights from UNC faculty
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Urologists from the University of North Carolina share insights into key advancements across the field of urologic oncology.
Advertisement
The field of urologic oncology is rapidly evolving. Urology Times® recently spoke with several urologists from the University of North Carolina, who shared insights into key advancements across the field.
Specifically, you'll hear from:
- Marc A. Bjurlin, DO, MSc, FACOS on the evolving role of mpMRI
- Kathryn H. Gessner, MD, PhD on the growing applications for genomic testing
- Mary Beth Westerman, MD on the amendment to microhematuria guideline
- Zachary Feuer, MD on a rapid access program for elevated PSA
Advertisement
Related to this article
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
4
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
5